Immunovant

IMVTNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$7.680 B

$37.18 +0.62%

Close of 21 Sept 2026

Revenue

—

Not reported

Earnings

-$505.6M

Loss-making

Shares outstanding

206,552,682

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#17RepligenRGEN$8.84B
#18VaxcytePCVX$8.77B
#19ImmunovantIMVT$7.68B
#20CG OncologyCGON$6.94B
#21Scholar RockSRRK$5.87B

What if Immunovant were worth as much as…

Open the what-if tool →

Gold $30.3T

$146,568.20

Per share 3,942× higher

Bitcoin $1.72T

$8,326.22

Per share 224× higher

Nvidia $5.48T

$26,530.07

Per share 714× higher

Or at a round number

$10.0B $20.0B $50.0B $100.0B

Where these numbers come from

Share counts and financials for Immunovant are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.